

**VIRGINIA BOARD OF PHARMACY
MINUTES OF PUBLIC HEARINGS TO PLACE CERTAIN CHEMICALS INTO
SCHEDULE I AND THE IMPLEMENTATION OF 2021 LEGISLATION FOR
PHARMACISTS INITIATING TREATMENT**

Tuesday, December 6, 2022

Department of Health Professions
Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233

CALL TO ORDER: Public hearings were called to order at 9:08AM

PRESIDING: Dale St. Clair, PharmD, Chairman

MEMBERS PRESENT: Ling Yuan, PharmD
Wendy C. Nash, PharmD
Larry Kocot, J.D.
Cheryl Garvin, RPh
Kristopher Ratliff, DPh
Patricia Richards-Spruill, RPh
William Lee, DPh

MEMBER ABSENT: Sarah Melton, PharmD

STAFF PRESENT: Caroline Juran, RPh, Executive Director
James Rutkowski, J.D., Assistant Attorney General
Arne W. Owens, Director, DHP
James Jenkins, Jr., RN, Chief Deputy Director, DHP
Erin Barrett, J.D., Senior Policy Analyst, DHP
Ellen B. Shinaberry, PharmD, Deputy Executive Director
Beth O'Halloran, RPh, Deputy Executive Director
Annette Kelley, MS, CSAC, Deputy Executive Director
Ryan Logan, RPh, Deputy Executive Director
Sorayah Haden, Executive Assistant
Patricia Mason, Individual Licensing Supervisor

QUORUM: With 8 members present, a quorum was established.

PLACING CHEMICALS INTO
SCHEDULE I:

Pursuant to article § 54.1-3443(D), the Virginia Department of Forensic Science (DFS) identified the following five compounds for recommended

inclusion into Schedule I of the Drug Control Act. A public hearing was convened to receive public comment on the subject.

The following compound is classified as a synthetic opioid. Compounds of this type have been placed in Schedule I (§ 54.1-3446(1)) in previous legislative sessions.

1. 2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (other name: 2-methyl butyryl fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.

Based on their chemical structures, the following compounds are expected to have hallucinogenic properties. Compounds of this type have been placed in Schedule I (§ 54.1-3446(3)) in previous legislative sessions.

2. 1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine (other names: 5-methoxy-3,4-methylenedioxyamphetamine, 3-methoxy MDA, MMDA), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

3. 1-[1-(3-chlorophenyl)cyclohexyl]-piperidine (other names: 3-Chloro Phencyclidine, 3Cl-PCP, 3-chloro PCP), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

Based on its chemical structure, the following compound is expected to have depressant properties. Compounds of this type have been placed in Schedule I (§ 54.1-3446(4)) in previous legislative sessions.

4. 7-bromo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one (other names: Desalkylgidazepam, Bromonordiazepam), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

The following compound is classified as a cannabimimetic agent. Compounds of this type have been placed in Schedule I (§ 54.1-3446(6)) in previous legislative sessions.

5. Methyl N-[(5-bromo-1H-indazol-3-yl)carbonyl]-3-methyl-valinate (other name: MDMB-5Br-INACA), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

PHARMACISTS INITIATING
TREATMENT:

A public hearing was convened to also receive public comment on proposed amendments to Chapters 20 and 21 of the Board's regulations regarding implementation of 2021 legislation for pharmacists initiating treatment. The proposed regulations will replace the emergency regulations which became effective on December 21, 2021 and expire June 21, 2023.

PUBLIC COMMENT:

Robyn Weimer, Chemistry Program Manager, DFS offered public comment addressing the five compounds. No other public comment was offered on this subject.

Christina Barrille, Executive Director, Virginia Pharmacists Association offered public comment urging the passing of the proposed regulations for pharmacists initiating treatment. She thanked the Virginia Boards of Pharmacy and Medicine and stakeholder partners such as the Medical Society of Virginia. No other public comment was offered on this subject.

MEETING ADJOURNED:

9:16am



Caroline D. Juran,
Executive Director

3/30/23

DATE: